8-K: Werewolf Therapeutics Reports Promising Q1 2025 Financial Results and Advances Clinical Programs

Werewolf Therapeutics announces positive Q1 2025 financial results, highlighted by progress in clinical trials for WTX-124 and WTX-330, and the development of INDUCER T cell engager molecules.

Summary

• Werewolf Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company's WTX-124 Phase 1/1b clinical trial is on track for data readouts and interactions with the FDA in the second half of the year.
• The first patient has been dosed in the Phase 1b/2 clinical trial of WTX-330.
• Werewolf is developing proprietary INDUCER T cell engager molecules, with a development candidate targeted by the end of the second quarter of 2025.
• The company's updated cash guidance provides runway into the fourth quarter of 2026.
• Cash and cash equivalents were $92.0 million as of March 31, 2025, compared to $111.0 million as of December 31, 2024.
• Research and development expenses were $13.1 million for the first quarter of 2025, compared to $12.9 million for the same period in 2024.
• General and administrative expenses were $4.9 million for the first quarter of 2025, compared to $5.0 million for the same period in 2024.
• Net loss was $18.1 million for the first quarter of 2025, compared to $16.2 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting clinical progress, financial stability, and innovative technology. While there are some negative aspects, such as the net loss, the overall tone is optimistic.

Positives

• The WTX-124 clinical trial is progressing as planned, with data readouts and FDA interactions expected in the second half of 2025.
• The initiation of the WTX-330 Phase 1b/2 clinical trial demonstrates advancement in the development of this molecule.
• The development of INDUCER T cell engager molecules expands Werewolf's pipeline and technology platform.
• The company's cash runway extends into the fourth quarter of 2026, providing financial stability for ongoing research and development.
• The company is launching a skin cancer awareness campaign to educate stakeholders on WTX-124 patient outcomes.

Negatives

• The company experienced a net loss of $18.1 million for the first quarter of 2025, which is higher than the $16.2 million loss for the same period in 2024.
• Cash and cash equivalents decreased from $111.0 million as of December 31, 2024, to $92.0 million as of March 31, 2025.

Risks

• The company's forward-looking statements are subject to substantial risks and uncertainties, including those related to the development of product candidates, regulatory approvals, and the company's ability to manage cash resources.
• Uncertainties exist regarding the availability and timing of results from preclinical studies and clinical trials.
• There is a risk that results from preclinical studies may not be predictive of the results of later preclinical studies and clinical trials.
• Preliminary or interim data from a clinical trial may not be predictive of future results.
• The company's ability to obtain additional cash resources to fund operating expenses and capital expenditure requirements is uncertain.

Future Outlook

The company anticipates sharing interim data from the WTX-124 Phase 1/1b clinical trial and engaging with regulatory authorities in the second half of 2025. Werewolf believes its existing cash and cash equivalents will be sufficient to fund operational expenses and capital expenditure requirements into the fourth quarter of 2026.

Management Comments

• Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, stated that the company continues to build on promising data and progress across its clinical-stage programs.
• Dr. Hicklin mentioned that Werewolf remains on track in its Phase 1/1b clinical trial evaluating WTX-124 to share interim data and meet with the FDA to discuss potential registrational pathways in the second half of this year.
• Dr. Hicklin also reported the recent initiation of a Phase 1b/2 clinical trial of WTX-330 to explore antitumor activity and optimize the exposure of the IL-12 INDUKINE molecule in the tumor microenvironment.
• Dr. Hicklin noted that Werewolf has been making significant progress towards nominating its first INDUCER T cell engager development candidate in the second quarter of 2025.

Industry Context

Werewolf Therapeutics is focused on developing conditionally activated therapeutics to stimulate the body's immune system for cancer treatment, addressing the limitations of conventional proinflammatory immune therapies. The company's PREDATOR platform and INDUKINE molecules aim to improve the therapeutic index of cytokines by targeting the tumor microenvironment.

Comparison to Industry Standards

• Werewolf's approach to conditionally activated cytokines is designed to overcome the toxicity issues associated with high-dose IL-2 therapies like aldesleukin (Proleukin), which, while effective in some patients with melanoma and renal cell carcinoma, are limited by severe side effects.
• The company's WTX-330 aims to improve upon recombinant human IL-12 therapies, which have also been limited by toxicity issues.
• Werewolf's INDUCER T cell engager molecules are designed to address the safety concerns of current T cell engagers, such as cytokine release syndrome, by using a novel CD3 masking strategy.

Stakeholder Impact

• Shareholders: The report provides an update on the company's financial performance and clinical development programs, which may influence investor confidence.
• Employees: The company's progress and financial stability can positively impact employee morale and job security.
• Patients: Advancements in clinical trials and the development of new therapies offer hope for improved treatment options.
• Partners: The report provides information on potential partnering opportunities for preclinical assets.

Next Steps

• Present interim data from the WTX-124 Phase 1/1b clinical trial in the second half of 2025.
• Engage with regulatory authorities to discuss potential registrational pathways for WTX-124 in the second half of 2025.
• Nominate the first INDUCER T cell engager development candidate in the second quarter of 2025.
• Optimize WTX-330 exposure in the tumor microenvironment in the Phase 1b/2 clinical trial.
• Open expansion arms in the Phase 1b/2 clinical trial for locally advanced or metastatic cutaneous melanoma, microsatellite stable colorectal cancer, and advanced non-Hodgkins lymphoma.

Key Dates

Keywords

Werewolf Therapeutics, WTX-124, WTX-330, INDUKER, Clinical Trial, Financial Results, Immunotherapy, Oncology, Biopharmaceutical, PREDATOR Platform